Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VF001-DP in Chronic Venous Leg Ulcers
NCT02973893Phase 2Unknown
- Sponsor
- Tissue Therapies
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Injectable Hydrogels, Implantable Devices, Implantable Hydrogels
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VitroGro ECM in chronic venous leg ulcer (VLU) (3 arms), sponsored by Tissue Therapies. Primary endpoint: Percentage reduction in the study ulcer area at 12 weeks. Status: unknown.
02
Drugs
VitroGro ECM
03
Conditions
chronic venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT02973893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973893.